Market Research Logo

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025

Summary

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over six million individuals in the 8MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, and Australia) and this prevalence is expected to grow to just shy of 7 million individuals by 2025. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease.

The RA market in the 8MM is expected to grow at a Compound Annual Growth Rate (CAGR) of 3.9% during the forecast period, from 2015 sales of $19.5 billion to sales of $28.5 billion in 2025.

The major drivers of growth in the global RA market during the forecast period are -

  • An increase in the prevalent cases of RA in all the markets, in part, due to an aging population.
  • The launch and continued uptake of biosimilars for all established biologics on the RA market (infliximab, etanercept, adalimumab, golimumab, certolizumab pegol, tocilizumab, abatacept, and rituximab) in all the markets covered in the report, which is expected to lead to an increase in patient volume by making treatments more accessible.
  • The early diagnosis and treatment of patients with RA to limit disease progression.


  • The RA market is dominated by Big Pharma, and most of the compounds in late-stage development are backed by a major pharmaceutical company. The major players in the RA market have extensive portfolios, and may enter into Phase I buyouts and partnerships at very early stages. It is especially common for these companies to form an early partnership for development in the Japanese market.

    Biosimilars for all established biologics are expected to launch in all 8MM by 2025, with the exception of etanercept in the US and certolizumab in Japan. Overall, the market share of biosimilars will account for 23% of the 8MM RA market in 2025. It is this potential segment of the RA market that Big Pharma companies such as Pfizer and Amgen have realized, and as such are pursuing their own biosimilar development programs.

    The report PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025 provides an overview of rheumatoid arthritis (RA), including etiology, pathophysiology, and country-specific diagnosis and treatment recommendations.

    In depth, this report provides the following analysis -
  • Provides comprehensive data split across different phases and emerging trends, specifically JAK inhibitors (such as Eli Lilly/Incyte’s Olumiant (baricitinib), novel biologics (such as AstraZeneca-MedImmune’s mavrilimumab), and biosimilars (such as Celltrion/Hospira/Pfizer’s Inflectra/Remsima, Samsung Bioepis/Biogen/Merck’s Flixabi and Benepali, Sandoz’s Erelzi, and Amgen’s Amjevita).
  • Provides annualized RA market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
  • Analysis of strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the RA biologics and biosimilars markets.
  • Analysis of the current and future market competition in the global RA market. Insightful review of the key industry and governmental drivers, restraints and challenges.


  • Companies mentioned in this report: AbbVie, Pfizer, Amgen, Johnson & Johnson, Eli Lilly, Bristol-Myers Squibb, UCB, Roche, GlaxoSmithKline, Novartis, Sanofi, AstraZeneca-MedImmune, Astellas, Daiichi Sankyo, Samsung Bioepis, Sandoz.

    Scope
    • Overview of rheumatoid arthritis (RA), including etiology, pathophysiology, and country-specific diagnosis and treatment recommendations.
    • Annualized RA market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
    • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the RA biologics and biosimilars markets.
    • Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically JAK inhibitors (such as Eli Lilly/Incyte’s Olumiant (baricitinib), novel biologics (such as AstraZeneca-MedImmune’s mavrilimumab), and biosimilars (such as Celltrion/Hospira/Pfizer’s Inflectra/Remsima, Samsung Bioepis/Biogen/Merck’s Flixabi and Benepali, Sandoz’s Erelzi, and Amgen’s Amjevita).
    • Analysis of the current and future market competition in the global RA market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
    Reasons to buy

    The report will enable you to -
    • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
    • Develop business strategies by understanding the trends shaping and driving the RA market.
    • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RA market in the future.
    • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
    • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
    • Track drug sales in the eight major RA markets from 2015-2025.
    • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


    1 Table of Contents
    1.1 List of Tables
    1.2 List of Figures
    2 Introduction
    2.1 Catalyst
    2.2 Related Reports
    2.3 Upcoming Related Reports
    3 Disease Overview
    3.1 Etiology and Pathophysiology
    3.1.1 Etiology
    3.1.2 Pathophysiology
    3.2 Symptoms
    3.3 Prognosis
    3.4 Quality of Life
    4 Epidemiology
    4.1 Disease Background
    4.2 Risk Factors and Comorbidities
    4.3 Global Trends
    4.3.1 Diagnosed Incidence
    4.3.2 Prevalence
    4.4 Forecast Methodology
    4.4.1 Sources Used
    4.4.2 Forecast Assumptions and Methods
    4.4.3 Sources Not Used
    4.5 Epidemiological Forecast for RA (2015-2025)
    4.5.1 Diagnosed Incident Cases
    4.5.2 Diagnosed Prevalent Cases
    4.5.3 Total Prevalent Cases
    4.6 Discussion
    4.6.1 Epidemiological Forecast Insight
    4.6.2 Limitations of the Analysis
    4.6.3 Strengths of the Analysis
    5 Disease Management
    5.1 Diagnosis and Treatment Overview
    5.1.1 Diagnosis
    5.1.2 Treatment Guidelines
    5.1.3 Leading Prescribed Drugs for the Treatment of RA
    5.1.4 Clinical Practice
    5.2 US
    5.3 France
    5.4 Germany
    5.5 Italy
    5.6 Spain
    5.7 UK
    5.8 Japan
    5.9 Australia
    6 Competitive Assessment
    6.1 Overview
    6.2 Product Profiles - Major Brands
    6.2.1 Enbrel (etanercept)
    6.2.2 Humira (adalimumab)
    6.2.3 Remicade (infliximab)
    6.2.4 Simponi (golimumab)
    6.2.5 Cimzia (certolizumab pegol)
    6.2.6 Orencia (abatacept)
    6.2.7 Actemra/RoActemra (tocilizumab)
    6.2.8 Rituxan/MabThera (rituximab)
    6.2.9 Inflectra/Remsima (infliximab biosimilar)
    6.2.10 Flixabi (infliximab biosimilar)
    6.2.11 Benepali (etanercept biosimilar)
    6.2.12 Erelzi (etanercept biosimilar)
    6.2.13 Amjevita (adalimumab biosimilar)
    6.2.14 Xeljanz (tofacitinib)
    6.2.15 Iguratimod/T-614
    6.2.16 Methotrexate (Numerous Brands)
    6.3 Biosimilars Assessment
    6.3.1 Introduction
    6.3.2 Biosimilars in the Immunology Community
    6.3.3 By the Numbers: Biosimilars in Development
    6.3.4 The Impact of Biosimilars Is Being Felt Throughout the Pharmaceutical Industry
    6.3.5 Uptake of Biosimilars for RA Is Expected to Vary by Market
    6.4 Other Therapies
    7 Unmet Needs and Opportunities
    7.1 Overview
    7.2 Development of Cost-Effective Therapies
    7.2.1 Unmet Need
    7.2.2 Gap Analysis
    7.2.3 Opportunity
    7.3 Biomarkers to Predict Responsiveness to Therapy
    7.3.1 Unmet Need
    7.3.2 Gap Analysis
    7.3.3 Opportunity
    7.4 Early Diagnosis of RA
    7.4.1 Unmet Need
    7.4.2 Gap Analysis
    7.4.3 Opportunity
    7.5 Personalized Treatment Approach
    7.5.1 Unmet Need
    7.5.2 Gap Analysis
    7.5.3 Opportunity
    8 Pipeline Assessment
    8.1 Overview
    8.2 Clinical Trial Mapping
    8.2.1 Clinical Trials by Class
    8.3 Promising Drugs in Clinical Development
    8.3.1 Sarilumab
    8.3.2 Sirukumab
    8.3.3 Clazakizumab
    8.3.4 Vobarilizumab (ALX-0016)
    8.3.5 Mavrilimumab
    8.3.6 Pralia (denosumab)
    8.3.7 Olumiant (baricitinib)
    8.3.8 Peficitinib
    8.3.9 Filgotinib
    8.3.10 Upadacitinib
    8.3.11 Piclidenoson
    8.4 Other Drugs in Development
    9 Current and Future Players
    9.1 Trends in Corporate Strategy
    9.2 Company Profiles
    9.2.1 AbbVie
    9.2.2 Pfizer
    9.2.3 Amgen
    9.2.4 Johnson & Johnson
    9.2.5 Eli Lilly
    9.2.6 Bristol-Myers Squibb
    9.2.7 UCB
    9.2.8 Roche
    9.2.9 GlaxoSmithKline
    9.2.10 Sanofi
    9.2.11 AstraZeneca- MedImmune
    9.2.12 Astellas
    9.2.13 Daiichi Sankyo
    9.2.14 Samsung Bioepis
    9.2.15 Sandoz
    10 Market Outlook
    10.1 Global Markets
    10.1.1 Forecast
    10.1.2 Drivers and Barriers - Global Issues
    10.2 US
    10.2.1 Forecast
    10.2.2 Key Events
    10.2.3 Drivers and Barriers
    10.3 5EU
    10.3.1 Forecast
    10.3.2 Key Events
    10.3.3 Drivers and Barriers
    10.4 Japan
    10.4.1 Forecast
    10.4.2 Key Events
    10.4.3 Drivers and Barriers
    10.5 Australia
    10.5.1 Forecast
    10.5.2 Key Events
    10.5.3 Drivers and Barriers
    11 Appendix
    11.1 Bibliography
    11.2 Abbreviations
    11.3 Methodology
    11.4 Forecasting Methodology
    11.4.1 Diagnosed RA Patients
    11.4.2 Percentage of Drug-Treated Patients
    11.4.3 Drugs Included in Each Therapeutic Class
    11.4.4 Launch and Patent Expiry Dates
    11.4.5 General Pricing Assumptions
    11.4.6 Individual Drug Assumptions
    11.4.7 Generic and Biosimilar Erosion
    11.4.8 Pricing of Pipeline Agents
    11.5 Primary Research - KOLs Interviewed for This Report
    11.6 Primary Research - Prescriber Survey
    11.7 About the Authors
    11.7.1 Analyst
    11.7.2 Therapy Area Director
    11.7.3 Epidemiologist
    11.7.4 Global Director of Therapy Analysis and Epidemiology
    11.8 About GlobalData
    11.9 Disclaimer
    1.1 List of Tables
    Table 1: Symptoms of RA
    Table 2: Risk Factors and Comorbidities of RA
    Table 3: 1987 ACR Diagnostic Criteria for RA
    Table 4: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of RA
    Table 5: 8MM, Sources Used to Forecast the Total Prevalent Cases of RA
    Table 6: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of RA
    Table 7: 8MM, Sources Used to Forecast Severity Segmentation of the Diagnosed Prevalent Cases of RA
    Table 8: 8MM, Sources Not Used in the Epidemiological Analysis of RA
    Table 9: 8MM, Diagnosed Incident Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025
    Table 10: 8MM, Age-Specific Diagnosed Incident Cases of RA, Both Sexes, N (Row %), 2015
    Table 11: 8MM, Sex-Specific Diagnosed Incident Cases of RA, Ages ≥18 Years, N (Row %), 2015
    Table 12: 8MM, Diagnosed Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025
    Table 13: 8MM, Age-Specific Diagnosed Prevalent Cases of RA, Both Sexes, N (Row %), 2015
    Table 14: 8MM, Sex-Specific Diagnosed Prevalent Cases of RA, Ages ≥18 Years, N (Row %), 2015
    Table 15: 8MM, Total Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025
    Table 16: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, N (Row %), 2015
    Table 17: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages ≥18 Years, N (Row %), 2015
    Table 18: 1987 ACR Diagnostic Criteria for RA
    Table 19: 2010 ACR/EULAR Diagnostic Criteria for RA
    Table 20: Treatment Guidelines for RA Used by Each Country in the 8MM
    Table 21: ACR 2015 Criteria for RA Remission and Low/Moderate/High Disease Activity
    Table 22: EULAR 2013 Criteria for RA Remission
    Table 23: Most-Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2015
    Table 24: RA Treatment Country Profile - US
    Table 25: RA Treatment Country Profile - France
    Table 26: RA Treatment Country Profile - Germany
    Table 27: RA Treatment Country Profile - Italy
    Table 28: RA Treatment Country Profile - Spain
    Table 29: RA Treatment Country Profile - UK
    Table 30: RA Treatment Country Profile - Japan
    Table 31: RA Treatment Country Profile - Australia
    Table 32: Leading Branded Treatments for RA, 2016
    Table 33: Product Profile - Enbrel
    Table 34: 10-Year, Open-Label Safety and Efficacy Trial of Enbrel: Efficacy Results at 11 Years for Completers
    Table 35: 10-Year, Open-Label Safety and Efficacy Trial of Enbrel: Overall Safety Results
    Table 36: Enbrel SWOT Analysis, 2016
    Table 37: Product Profile - Humira
    Table 38: Humira SWOT Analysis, 2016
    Table 39: Product Profile - Remicade
    Table 40: Remicade SWOT Analysis, 2016
    Table 41: Product Profile - Simponi
    Table 42: Simponi SWOT Analysis, 2016
    Table 43: Product Profile - Cimzia
    Table 44: Cimzia SWOT Analysis, 2016
    Table 45: Product Profile - Orencia
    Table 46: Orencia SWOT Analysis, 2016
    Table 47: Product Profile - Actemra
    Table 48: Actemra SWOT Analysis, 2016
    Table 49: Product Profile - Rituxan
    Table 50: Rituxan SWOT Analysis, 2016
    Table 51: Product Profile - Inflectra/Remsima
    Table 52: Inflectra/Remsima SWOT Analysis, 2016
    Table 53: Product Profile - Flixabi
    Table 54: Flixabi SWOT Analysis, 2016
    Table 55: Product Profile - Benepali
    Table 56: Benepali SWOT Analysis, 2016
    Table 57: Product Profile - Erelzi
    Table 58: Erelzi SWOT Analysis, 2016
    Table 59: Product Profile - Amjevita
    Table 60: Amjevita SWOT Analysis, 2016
    Table 61: Product Profile - Xeljanz
    Table 62: ORAL Standard ACR20 Responses for Tofacitinib vs. Humira and Placebo at Month 6
    Table 63: ORAL Step ACR20, 50, and 70 Responses for Xeljanz vs. Placebo at Month 6
    Table 64: Xeljanz SWOT Analysis, 2016
    Table 65: Product Profile - Iguratimod
    Table 66: Iguratimod SWOT Analysis, 2016
    Table 67: Product Profile - MTX
    Table 68: MTX SWOT Analysis, 2016
    Table 69: Marketed and Pipeline Biosimilars for RA, 2016
    Table 70: Biosimilar Legislations Across the 8MM
    Table 71: Physician Uptake of Biosimilar Products for RA Across the 8MM, 2016
    Table 72: Summary of Minor Therapeutic Drug Classes Used to Treat RA, 2016
    Table 73: Unmet Needs and Opportunities in RA, 2016
    Table 74: Comparison of Therapeutic Drug Classes in Development for RA, 2016
    Table 75: Product Profile - Sarilumab
    Table 76: MOBILITY Study Part, A, Results for Sarilumab at Week 12
    Table 77: MOBILITY Study Part B, Results for Sarilumab at Week 52
    Table 78: Safety Results of the Sarilumab Phase III SARIL-RA-ASCERTAIN Trial
    Table 79: Laboratory Results of Sarilumab Phase III SARIL-RA-ASCERTAIN Trial
    Table 80: Sarilumab SWOT Analysis, 2016
    Table 81: Product Profile - Sirukumab
    Table 82: SIRROUND-D Study Results for Sirukumab
    Table 83: Sirukumab SWOT Analysis, 2016
    Table 84: Product Profile - Clazakizumab
    Table 85: Phase IIb Study of Clazakizumab: ACR Responses After 12 Weeks
    Table 86: Phase IIb Study of Clazakizumab: ACR Responses After 24 Weeks
    Table 87: Clazakizumab SWOT Analysis, 2016
    Table 88: Product Profile - Vobarilizumab
    Table 89: Phase IIb Study of Vobarilizumab: Efficacy Results for ITT Population at Week 12
    Table 90: Vobarilizumab SWOT Analysis, 2016
    Table 91: Product Profile - Mavrilimumab
    Table 92: EARTH-EXPLORER 2 Results for Mavrilimumab at 24 Weeks
    Table 93: EARTH-EXPLORER 2 Results for Mavrilimumab at 24 Weeks
    Table 94: Mavrilimumab SWOT Analysis, 2016
    Table 95: Product Profile - Denosumab
    Table 96: Denosumab SWOT Analysis, 2016
    Table 97: Product Profile - Baricitinib
    Table 98: Phase III RA-BEAM Study Results for Baricitinib at Week 12
    Table 99: Phase III RA-BEAM Study Results for Baricitinib at Week 24
    Table 100: Phase III RA-BEACON Study Results for Baricitinib at Week 12 and Week 24
    Table 101: Phase III RA-BUILD Study Results for Baricitnib at Week 12 and Week 24
    Table 102: Baricitinib SWOT Analysis, 2016
    Table 103: Product Profile - Peficitinib
    Table 104: Peficitinib SWOT Analysis, 2016
    Table 105: Product Profile - Filgotinib
    Table 106: DARWIN I Study Results for Filgotinib at Week 12
    Table 107: DARWIN I Study Results for Filgotinib at Week 24
    Table 108: DARWIN II Study Results for Filgotinib at Week 12
    Table 109: DARWIN II Study Results for Filgotinib at Week 24
    Table 110: Filgotinib SWOT Analysis, 2016
    Table 111: Product Profile - Upadacitinib
    Table 112: Upadacitinib Phase IIb BALANCE-I Trial, ACR Responses at Week 12
    Table 113: Upadacitinib Phase IIb BALANCE-II Trial, ACR Responses at Week 12
    Table 114: Upadacitinib SWOT Analysis, 2016
    Table 115: Product Profile - Piclidenoson
    Table 116: Piclidenoson SWOT Analysis, 2016
    Table 117: Drugs in Phase II of Development for RA, 2016
    Table 118: Key Companies in the RA Market, 2016
    Table 119: AbbVie’s RA Portfolio Assessment, 2016
    Table 120: AbbVie SWOT Analysis in RA, 2015-2025
    Table 121: Pfizer’s RA Portfolio Assessment, 2016
    Table 122: Pfizer SWOT Analysis in RA, 2015-2025
    Table 123: Amgen’s RA Portfolio Assessment, 2016
    Table 124: Amgen SWOT Analysis in RA, 2015-2025
    Table 125: J&J’s RA Portfolio Assessment, 2016
    Table 126: J&J SWOT Analysis in RA, 2015-2025
    Table 127: Eli Lilly’s RA Portfolio Assessment, 2016
    Table 128: Eli Lilly SWOT Analysis in RA, 2015-2025
    Table 129: BMS’ RA Portfolio Assessment, 2016
    Table 130: BMS SWOT Analysis in RA, 2015-2025
    Table 131: UCB’s RA Portfolio Assessment, 2016
    Table 132: UCB SWOT Analysis in RA, 2015-2025
    Table 133: Roche’s RA Portfolio Assessment, 2016
    Table 134: Roche SWOT Analysis in RA, 2015-2025
    Table 135: GSK’s RA Portfolio Assessment, 2016
    Table 136: GSK SWOT Analysis in RA, 2015-2025
    Table 137: Sanofi’s RA Portfolio Assessment, 2016
    Table 138: Sanofi SWOT Analysis in RA, 2015-2025
    Table 139: AstraZeneca/MedImmune’s RA Portfolio Assessment, 2016
    Table 140: AstraZeneca/MedImmune SWOT Analysis in RA, 2015-2025
    Table 141: Astellas’ RA Portfolio Assessment, 2016
    Table 142: Astellas SWOT Analysis in RA, 2015-2025
    Table 143: Daiichi Sankyo’s RA Portfolio Assessment, 2016
    Table 144: Daiichi Sankyo SWOT Analysis in RA, 2015-2025
    Table 145: Samsung Bioepis’ RA Portfolio Assessment, 2016
    Table 146: Samsung Bioepis’ SWOT Analysis in RA, 2015-2025
    Table 147: Sandoz’s RA Portfolio Assessment, 2016
    Table 148: Sandoz’s SWOT Analysis in RA, 2015-2025
    Table 149: Global RA Market - Drivers and Barriers, 2015-2025
    Table 150: Key Events Impacting Sales for RA in the US, 2015-2025
    Table 151: RA Market in the US - Drivers and Barriers, 2015-2025
    Table 152: Key Events Impacting Sales for RA in the 5EU, 2015-2025
    Table 153: RA Market in 5EU - Drivers and Barriers, 2015-2025
    Table 154: Key Events Impacting Sales for RA in Japan, 2015-2025
    Table 155: RA Market in Japan - Drivers and Barriers, 2013-2023
    Table 156: Key Events Impacting Sales for RA in Australia, 2015-2025
    Table 157: RA Market in Australia - Drivers and Barriers, 2013-2023
    Table 158: 8MM, Key Launch Dates of RA Products
    Table 159: 8MM, Key Patent Expiries of RA Products
    Table 160: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
    1.2 List of Figures
    Figure 1: Normal Synovial Joint and Synovial Joint with RA
    Figure 2: Cellular and Cytokine Targets for the Current RA Drugs
    Figure 3: 8MM, Diagnosed Incident Cases of RA, Ages ≥18 Years, Both Sexes, N, 2015-2025
    Figure 4: 8MM, Age-Specific Diagnosed Incident Cases of RA, Both Sexes, N, 2015
    Figure 5: 8MM, Sex-Specific Diagnosed Incident Cases of RA, Ages ≥18 Years, N, 2015
    Figure 6: 8MM, Age-Standardized Diagnosed Incidence of RA, Ages ≥18 Years, Cases per 100,000 Population, 2015
    Figure 7: 8MM, Diagnosed Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025
    Figure 8: 8MM, Age-Specific Diagnosed Prevalent Cases of RA, Both Sexes, N, 2015
    Figure 9: 8MM, Sex-Specific Diagnosed Prevalent Cases of RA, Ages ≥18 Years, N, 2015
    Figure 10: 8MM, Age-Standardized Diagnosed Prevalence of RA, Ages ≥18 Years, %, 2015
    Figure 11: 8MM, Diagnosed Prevalent Cases of RA by Severity, Both Sexes, Ages ≥18 Years, N, 2015
    Figure 12: 8MM, Total Prevalent Cases of RA, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025
    Figure 13: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, N, 2015
    Figure 14: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages ≥18 Years, N, 2015
    Figure 15: 8MM, Age-Standardized Total Prevalence of RA, Ages ≥18 Years, N, 2015
    Figure 16: Disease Management Flowchart for Early RA - ACR 2015
    Figure 17: Disease Management Flowchart for Established RA - ACR 2015
    Figure 18: Flowchart for the Management of RA - EULAR 2013
    Figure 19: Biosimilar Prescribing Habits in RA Across the 8MM, 2016
    Figure 20: RA Clinical Trials by Drug Class, 2016
    Figure 21: RA Phase II-III Pipeline, 2016
    Figure 22: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2015-2025
    Figure 23: Clinical and Commercial Positioning of Sarilumab
    Figure 24: Clinical and Commercial Positioning of Sirukumab
    Figure 25: Clinical and Commercial Positioning of Clazakizumab
    Figure 26: Clinical and Commercial Positioning of Vobarilizumab
    Figure 27: Clinical and Commercial Positioning of Mavrilimumab
    Figure 28: Clinical and Commercial Positioning of Denosumab in RA
    Figure 29: Clinical and Commercial Positioning of Baricitinib
    Figure 30: Clinical and Commercial Positioning of Peficitinib
    Figure 31: Clinical and Commercial Positioning of Filgotinib
    Figure 32: Clinical and Commercial Positioning of Upadacitinib
    Figure 33: Clinical and Commercial Positioning of Piclidenoson
    Figure 34: Company Portfolio Gap Analysis in RA, 2015-2025
    Figure 35: Global Sales for RA by Region, 2015-2025
    Figure 36: Sales for RA in the US by Drug Class, 2015-2025
    Figure 37: Sales for RA in the 5EU by Drug Class, 2015-2025
    Figure 38: Sales for RA in Japan by Drug Class, 2015-2025
    Figure 39: Sales for RA in Australia by Drug Class, 2015-2025

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report